Under construction – not a live service
Sign in
Not yet taking people in GermanyNo phase

Catheter Ablation for Atrial Fibrillation After Mitral Valve Repair for Leaky Valve

Compares catheter ablation with usual care in atrial fibrillation after mitral valve repair.

Plain-language title generated from the registry record
Registry title: Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair

Key facts

Where
Cologne, Frankfurt, Hamburg, and Münster, GermanySee the 4 sites

Where in Germany

  • University Hospital CologneCologne, GermanyNo longer taking part
  • University Heart and Vascular Center FrankfurtFrankfurt, GermanyNo longer taking part
  • Asklepios Hospital St. GeorgHamburg, GermanyNo longer taking part
  • University Hospital MunsterMünster, GermanyNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Atrial Fibrillation Network
Trial code
NCT07380932
Record updated
10 September 2026
Original description
CABA-MiTRA-AFNET12 is a non-commercial, parallel-group, prospective, randomised, open, blinded endpoint assessment (PROBE), multi-centre, therapy strategy trial. The trial investigates patients with severe mitral valve regurgitation who have undergone transcatheter edge-to-edge mitral valve repair (M-TEER) and have concomitant atrial fibrillation (AF). The objective is to assess whether catheter ablation of AF is superior to standard-of-care treatment in patients after TEER in reduction of major adverse cardiovascular and cerebrovascular events (MACCE).Read full original descriptionShow less

Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair

CABA-MiTRA-AFNET12 is a non-commercial, parallel-group, prospective, randomised, open, blinded endpoint assessment (PROBE), multi-centre, therapy strategy trial. The trial investigates patients with severe mitral valve regurgitation who have undergone transcatheter edge-to-edge mitral valve repair (M-TEER) and have concomitant atrial fibrillation (AF). The objective is to assess whether catheter ablation of AF is superior to standard-of-care treatment in patients after TEER in reduction of major adverse cardiovascular and cerebrovascular events (MACCE).

Inclusion: Patients with ECG-documented atrial fibrillation (AF); Transcatheter edge-to-edge mitral-valve repair (TEER) for severe functional mitral valve regurgitation (MR) with successful result (less than moderate MR, gradient < 5 mmHg) performed within a period of minimum of 30 days and a maximum of 6 months. Moderate residual MR is eligible if no further mitral valve intervention or surgery is planned and patient is stable for > 3 months; Provision of signed informed consent.

Exclusion: Previous ablation procedure for AF; Acute coronary syndrome, cardiac surgery, angioplasty, or cerebrovascular accident within 2 months prior to enrolment; Untreated hypothyroidism or hyperthyroidism requiring therapy; Indication for cardiac resynchronization therapy; Age <18 years; Current pregnancy, breastfeeding, or women not using reliable contraceptive measures during fertility age; Patient not suitable for AF ablation; Enrolment in another randomised study; Mental or physical inability to participate in the study; Planned cardiovascular intervention or operation; Life expectancy ≤ 12 month.

ClinicalTrials.gov NCT07380932